Pain and Rheumatoid Arthritis Science
HT-6184: An investigational Approach to Treating Rheumatoid Arthritis
HT-6184: Investigational Treatment for Rheumatoid Arthritis
Targeting the NLRP3 Inflammasome in Rheumatoid Arthritis (RA)
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and systemic symptoms. 8 The NLRP3 inflammasome has been suggested to play a role in RA by promoting the release of pro-inflammatory cytokines, such as IL-1β and IL-18. 9 HT-6184 is being investigated for its potential to inhibit the NLRP3 inflammasome, thereby modulating inflammation in RA patients.
While preclinical studies have shown reductions in cytokine levels, the potential benefit of HT-6184 in clinical settings remains to be established. Halia Therapeutics is planning to conduct clinical trials to evaluate the safety and potential benefits for patients with RA.
Investigational Status: HT-6184 is investigational and is not approved for the treatment of rheumatoid arthritis. Future clinical studies are needed to evaluate its safety and efficacy in this setting.
HT-6184: Investigational Use for Post-Operative Pain
Modulating Inflammation for Pain Management
HT-6184 is being studied for its potential in managing post-operative pain by targeting the NLRP3 inflammasome. In preclinical models, the inflammasome has been linked to inflammation and pain following surgery.10 Initial findings suggest that inhibiting NLRP3 may reduce the release of pro-inflammatory cytokines involved in pain signaling, but these data require validation in clinical settings.11
Investigational Status: The use of HT-6184 for pain management is still investigational. Its efficacy for managing post-operative pain has not been established, and it is not approved for this indication. Halia Therapeutics, in May 2024, completed a placebo-controlled phase 2 clinical trial to evaluate the attenuating effect of HT-6184 on the C-reactive protein (CRP) of subjects with acute trauma consequent to the surgical removal of two or more third molars, at least one of which must be partially or fully impacted in the mandibular bone.
Obesity
Almost half of US adults are obese or severely obese. Lack of physical activity, unhealthy eating behavior, and, in some cases, genetics contribute to obesity. Halia is developing investigational treatments to combat obesity.
Pain and Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is an autoimmune condition where the immune system—normally the body's defender against infection and disease—attacks its own tissues. This results in pain, swelling, stiffness, and loss of joint function. Halia is developing an investigational treatment for both RA and post-surgical pain.
Alzheimer's Disease
Alzheimer’s disease involves parts of the brain that control memory, language, problem-solving, and other thinking abilities. It can seriously affect a person’s ability to carry out daily activities. Halia is developing a potentially relevant pathway and investigational treatment for Alzheimer’s.
Parkinson's Disease
Parkinson’s disease is a progressive disorder that affects the nervous system and the parts of the body controlled by the nerves. Tremors, stiffness, or slowing of movement are typical symptoms. Halia is developing a potential brain-penetrant compound to treat the disease.